Experienced in Transient Ischemic Attack (TIA)

Chang X. Shu

139 Middle Renmin Road, 
Changsha, CN 
Experienced in Transient Ischemic Attack (TIA)
139 Middle Renmin Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Chang Shu practices in Changsha, China. Mr. Shu is rated as an Experienced expert by MediFind in the treatment of Transient Ischemic Attack (TIA). His top areas of expertise are Aortic Dissection, Thoracic Aortic Aneurysm, Aberrant Subclavian Artery, Angioplasty, and Aneurysm Repair.

His clinical research consists of co-authoring 677 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Transient Ischemic Attack (TIA).

Gender
Male

Locations

139 Middle Renmin Road, Changsha, 410011, China
Other Locations
1095 Jie Fang Avenue, Wuhan, 430030, China
17 Qinghuadonglu Road, Beijing, 100083, China
238 Jiefang Road, Wuhan, 430060, China
No.71 Xinmin Street, Changchun, 130021, China
68 Changle Road, Nanjing, 210006, China
69 Xijunyuan Road, Xi'an, 710002, China
Hangkong Road 13, Wuhan, China
193 Tunxi Road, Hefei, 230009, China
Central South University 139 Renmin Middle Road, Changsha, 410011, China
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY：A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY：A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Genetic, Other
Study Drug: NL003 Hepatocyte Growth Factor cDNA Hybrid
Study Phase: Phase 3
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Genetic, Other
Study Drug: NL003 Hepatocyte Growth Factor-X7 cDNA Hybrid
Study Phase: Phase 3
Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities-A Phase II Multi-center Randomised Controlled Trial
Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities-A Phase II Multi-center Randomised Controlled Trial
Enrollment Status: Unknown
Publish Date: March 10, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

677 Total Publications

An unexpected secondary iliac-enteric fistula after endovascular repair of a tuberculous-infected iliac pseudoaneurysm.
An unexpected secondary iliac-enteric fistula after endovascular repair of a tuberculous-infected iliac pseudoaneurysm.
Journal: European heart journal
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shu's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 123 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile